This pathway can be activated not only by its primary ligand, Hepatocyte Growth Factor (HGF), but also through interactions with other ligands.[13] In several types of cancers, activation of MET has been well‐documented to promote tumor progression by creating an immunosuppressive TIME.[14, 15, 16] However, the specific effects of MET activation on the TIME in PDAC remain poorly understood and warrant further investigation. The gene discussed is MET; the disease is cancer.